NYSE:IQV - Iqvia Stock Price, Forecast & News

Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

Iqvia Holdings Inc (NYSE:IQV) released its earnings results on Wednesday, February, 12th. The medical research company reported $1.74 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.72 by $0.02. The medical research company had revenue of $2.90 billion for the quarter, compared to analyst estimates of $2.85 billion. Iqvia had a net margin of 1.72% and a return on equity of 17.65%. The firm's quarterly revenue was up 7.7% on a year-over-year basis. During the same period in the prior year, the business earned $1.50 EPS. View Iqvia's Earnings History.

Iqvia is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for Iqvia.

Iqvia updated its FY20 earnings guidance on Wednesday, February, 12th. The company provided earnings per share (EPS) guidance of $7.15-7.35 for the period, compared to the Thomson Reuters consensus estimate of $7.22. The company issued revenue guidance of 11.775-12.000 billion, compared to the consensus revenue estimate of $11.84 billion.

17 brokerages have issued 1 year price targets for Iqvia's shares. Their forecasts range from $136.38 to $200.00. On average, they expect Iqvia's share price to reach $176.21 in the next year. This suggests a possible upside of 7.2% from the stock's current price. View Analyst Price Targets for Iqvia.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 17 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iqvia.

Media headlines about IQV stock have been trending very negative recently, InfoTrie reports. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Iqvia earned a coverage optimism score of -3.0 on InfoTrie's scale. They also gave news headlines about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Iqvia.

Iqvia saw a decline in short interest in the month of January. As of January 31st, there was short interest totalling 3,250,000 shares, a decline of 5.2% from the January 15th total of 3,430,000 shares. Based on an average daily volume of 1,300,000 shares, the days-to-cover ratio is currently 2.5 days. Currently, 1.8% of the shares of the stock are sold short. View Iqvia's Current Options Chain.

Some companies that are related to Iqvia include Incyte (INCY), EXACT Sciences (EXAS), PPD (PPD), Icon (ICLR), Charles River Laboratories Intl. (CRL), PRA Health Sciences (PRAH), Syneos Health (SYNH), Exelixis (EXEL), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Intrexon (XON), Sorrento Therapeutics (SRNE), Anavex Life Sciences (AVXL) and STARPHARMA HOLD/S (SPHRY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Iqvia investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Paypal (PYPL), Allergan (AGN) and Accenture (ACN).

Iqvia's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include State Street Corp (4.02%), Jackson Square Partners LLC (2.68%), FMR LLC (2.16%), Goldman Sachs Group Inc. (1.12%), Investec Asset Management LTD (1.04%) and Farallon Capital Management LLC (0.96%). Company insiders that own Iqvia stock include Ari Bousbib, Canada Pension Plan Investment, Cpp Investment Board Private H, Group Holdings (Sbs) Advis Tpg, James H Erlinger III, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Robert Parks, Ronald A Rittenmeyer and W Richard Staub. View Institutional Ownership Trends for Iqvia.

IQV stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Farallon Capital Management LLC, Renaissance Technologies LLC, Citigroup Inc., AMF Pensionsforsakring AB, First Trust Advisors LP, Jackson Square Partners LLC and Castleark Management LLC. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Group Holdings (Sbs) Advis Tpg, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell and W Richard Staub. View Insider Buying and Selling for Iqvia.

IQV stock was purchased by a variety of institutional investors in the last quarter, including AustralianSuper Pty Ltd, Goldman Sachs Group Inc., Point72 Asset Management L.P., Loomis Sayles & Co. L P, Bessemer Group Inc., Assenagon Asset Management S.A., State Street Corp and MUFG Securities EMEA plc. View Insider Buying and Selling for Iqvia.

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IQV stock can currently be purchased for approximately $164.32.

Iqvia has a market capitalization of $31.88 billion and generates $11.09 billion in revenue each year. The medical research company earns $191 million in net income (profit) each year or $5.94 on an earnings per share basis. Iqvia employs 58,000 workers across the globe.View Additional Information About Iqvia.

The official website for Iqvia is http://www.iqvia.com/.

Iqvia's mailing address is 4820 EMPEROR BLVD, DURHAM NC, 27703. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]